Introduction
============

Both the efficacy and safety of warfarin anticoagulation in patients with atrial fibrillation (AF) are strongly dependent on the intensity of anticoagulation measured as the international normalized ratio (INR). The risk of ischemic stroke increases with INR levels \<1.8, and the risk of intracranial hemorrhage increases sharply at INR levels \>3.5.^[@b1]^ These findings support the standard "therapeutic" INR range of 2.0 to 3.0 for atrial fibrillation.^[@b2]--[@b4]^ A commonly used summary of the quality of warfarin anticoagulation is the linearly interpolated percent time in the therapeutic range (TTR).^[@b5]--[@b7]^ While many patient‐ and system‐level variables have been demonstrated to affect the INR, and there have been analyses of variation of average TTR at the institutional or geographic level,^[@b8]--[@b9]^ there are relatively few large studies assessing the impact of patient features on TTR at the level of the individual patient.^[@b10]^ In the current study, we explored individual and regional determinants of TTR among patients randomly allocated to warfarin in the global ROCKET AF (Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) double‐blind trial of rivaroxaban versus adjusted‐dose warfarin in patients with atrial fibrillation.^[@b11]--[@b12]^

Methods
=======

The design, conduct, and main results of the ROCKET AF trial have been presented previously.^[@b11]--[@b12]^ In brief, rivaroxaban (20 mg daily; 15 mg daily in patients with creatinine clearance of 30 to 49 mL/min) was compared with adjusted‐dose warfarin (INR point target of 2.5, INR range 2.0 to 3.0) for the prevention of stroke or systemic embolism. Patients with electrocardiographically documented nonvalvular atrial fibrillation at moderate to high risk of stroke were recruited at 1178 participating sites in 45 countries. Elevated risk was indicated by a history of stroke, transient ischemic attack (TIA), or systemic embolism or ≥2 of the following: heart failure or left ventricular ejection fraction ≤35%, hypertension, age ≥75 years, or diabetes mellitus (CHADS~2~ score ≥2).^[@b13]^ The proportion of patients without prior ischemic stroke, TIA, or systemic embolism and ≤2 risk factors was limited to 10% of the cohort by region; the remainder required either prior thromboembolism or ≥3 risk factors. Investigators were chosen on the basis of performance in clinical trials and access to large clinical practices that included patients with atrial fibrillation. We do not have comprehensive information on recruiting physicians\' specialty status. Warfarin dosing was managed by local physicians based on INR values generated by a standard point‐of‐care device (HemoSense, San Jose, CA). While physicians were reminded about the INR target of the trial and the need for monthly INR tests even when patients\' anticoagulation status was stable,^[@b14]^ the study did not provide specific treatment algorithms for anticoagulation management. Patients with \<6 weeks of exposure to vitamin K antagonist (VKA) medication immediately before entry into the trial were considered VKA naïve.

Statistical Analysis
--------------------

For the current analyses, patients were included if they had been assigned to warfarin in the ROCKET AF trial and took ≥1 dose of warfarin and had ≥1 INR test. Daily INR values between tests were imputed using the Rosendaal technique,^[@b6]^ and individual patient‐level TTR (i‐TTR) was calculated as the proportion of daily values within a strict range of INR 2.0 to 3.0. This included time during the initiation of warfarin at the start of the trial and after temporary interruptions but did not include time during temporary interruptions of ≥7 days or any time after permanent discontinuation. Only 0.18% of inter‐INR test intervals were \>8 weeks. Univariable relationships between baseline variables and i‐TTR were assessed with single‐predictor linear regression models. A multivariable model was developed using multiple linear regression in which a set of independent predictors was chosen in stepwise fashion from a set of candidate predictors. These candidates were age, sex, geographic region, body mass index, systolic and diastolic blood pressures, atrial fibrillation type, hypertension, diabetes, prior stroke or TIA, coronary artery disease, chronic obstructive pulmonary disease, peripheral artery disease, prior gastrointestinal bleed, liver disease, alcohol consumption in the past 12 months, CHADS~2~ score, estimated glomerular filtration rate (Modification of Diet in Renal Disease equation),^[@b15]^ hemoglobin, patient medications, and type of prior VKA experience. Only variable values at entry to the study were used. Multivariable models were developed both with and without a random effect for center; we report only the results for the models without a random effect for center, because both modeling approaches produced highly similar results. Regional and country mean i‐TTRs were unweighted averages of i‐TTR values for all individuals within the given region or country, respectively.

The relationship between geographic region and i‐TTR was further characterized using linear regression models with region as the only predictor within subgroups defined by prior VKA experience, both for i‐TTR and for i‐TTR excluding the first 90 days of warfarin therapy. For the current analysis, we grouped the countries involved in the ROCKET AF trial into the following regions: East Asia (China, Hong Kong, Korea, Malaysia, Philippines, Singapore, Thailand, and Taiwan); India; Eastern Europe (Bulgaria, Czech Republic, Greece, Hungary, Lithuania, Poland, Romania, Russia, Turkey, and Ukraine); Western Europe and similar (Western Europe/similar: Australia, Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, Great Britain, Israel, Italy, Netherlands, Norway, New Zealand, and Sweden); South Africa; Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Venezuela); and Canada/United States. These regional groupings were modified from those used in the primary trial report to provide more cultural and ethnic homogeneity.^[@b12]^ Analyses done with the original regional groupings reproduced the same patterns of regional effect on average i‐TTR although the overall *R*^2^ values for the multivariable models were modestly reduced (data not shown). We did not include terms for both region and race in the same multivariable models because the 2 were almost completely collinear. We summarize stroke risk using the CHADS~2~ score.^[@b13]^ Statistical significance of differences in the width of distributions of INR values across regions was assessed using the Miller jackknife technique.^[@b16]^

Human Subjects
--------------

All individuals enrolled in the study gave informed consent. All appropriate national regulatory authorities and ethics committees at participating centers approved the study. An international executive committee designed the study and takes responsibility for the accuracy and completeness of all analyses.

Results
=======

Baseline Patient Features
-------------------------

The ROCKET AF trial recruited atrial fibrillation patients at high risk for ischemic stroke. In the subpopulation (n=6983) included in the current analysis, the mean age was 71 years (median 73 years), 61% were male, 52% had had a prior stroke or TIA, and the mean CHADS~2~ stroke risk score was 3.3. A total of 83% were white, 12% were Asian, and there was a small representation of other racial/ethnic groups. Enrolled patients came from a broad set of geographic regions: 38% from Eastern Europe, 19% from Canada/United States, 16% from Western Europe/similar, 13% from Latin America, and 10% from East Asia (Table[1](#tbl01){ref-type="table"}). Thirty‐seven percent of patients were VKA naïve. Of the 4387 patients taking VKAs before entry into the trial, 1334 were not taking warfarin (Table[2](#tbl02){ref-type="table"}). Detailed features of patients participating in the ROCKET AF trial, stratified by geographic region, are presented in Table S1.

###### 

Mean i‐TTR by Baseline Characteristics: Clinical and Demographic Features

  Baseline Variable                                 N (%)        i‐TTR (Mean %)   Univariable *P* Value
  ------------------------------------------------- ------------ ---------------- -----------------------
  Age, y                                            \<0.0001                      
  \<73                                              3487 (50)    53.6±20.9        
  ≥73                                               3496         56.8±21.5        
  Sex                                               \<0.0001                      
  Male                                              4242 (61)    56.4±21.2        
  Female                                            2741         53.3±21.3        
  Race                                              \<0.0001                      
  White                                             5829 (83)    56.3±20.9        
  African American                                  83 (1)       51.9±21.0        
  Asian                                             872 (12)     48.3±22.4        
  American Indian/Alaskan                           10           51.2±19.1        
  Hawaiian/ Pacific Islander                        4            60.1±12.5        
  Other                                             185 (3)      52.6±21.7        
  Region                                            \<0.0001                      
  East Asia                                         727 (10)     50.4±21.4        
  India                                             130 (2)      35.9±23.3        
  Eastern Europe                                    2663 (38)    49.7±21.2        
  Western Europe/similar                            1088 (16)    63.2±18.5        
  South Africa                                      124 (2)      54.8±22.1        
  Latin America                                     924 (13)     55.2±20.0        
  Canada/ United States                             1327 (19)    64.1±18.2        
  BMI, kg/m^2^                                      0.0003                        
  \<28                                              3426 (49)    54.3±21.4        
  ≥28                                               3553         56.0±21.1        
  Systolic BP, mm Hg                                0.0005                        
  \<130                                             2675 (38)    56.8±20.8        
  ≥130                                              4300         54.2±21.5        
  AF type                                           0.79                          
  Persistent                                        5648 (81)    55.1±21.5        
  Paroxysmal                                        1239 (18)    55.3±20.5        
  New onset/ diagnosis                              96 (1)       56.5±19.5        
  Hypertension                                      0.055                         
  Absence                                           649          56.7±21.1        
  Presence                                          6334 (91)    55.0±21.3        
  Diabetes                                          0.61                          
  Absence                                           4230         55.3±21.3        
  Presence                                          2753 (39)    55.0±21.2        
  Prior stroke or TIA                               0.087                         
  Absence                                           3338         55.6±21.2        
  Presence                                          3645 (52)    54.8±21.3        
  Congestive heart failure                          \<0.0001                      
  Absence                                           2642         59.0±20.7        
  Presence                                          4340 (62)    52.9±21.2        
  eGFR (MDRD),^[@b15]^ mL/min per 1.73 m^2^         0.016                         
  \<68                                              3431 (49)    55.3±21.2        
  ≥68                                               3548         55.0±21.4        
  Baseline hemoglobin, g/L                          0.0052                        
  \<10.0                                            2469 (35)    53.5±21.5        
  ≥10.0                                             4510         56.1±21.1        
  CAD                                               \<0.0001                      
  Absence                                           5294         54.6±21.3        
  Presence                                          1689 (24)    57.0±21.0        
  COPD                                              0.053                         
  Absence                                           6259         55.4±21.3        
  Presence                                          719 (10)     53.7±21.1        
  PAD                                               0.047                         
  Absence                                           6558         55.1±21.3        
  Presence                                          425 (6)      57.2±20.7        
  Prior GI bleed                                    \<0.0001                      
  Absence                                           6713         55.0±21.3        
  Presence                                          270 (4)      60.7±19.3        
  Liver disease                                     0.012                         
  Absence                                           6616         55.3±21.2        
  Presence                                          367 (5)      52.5±21.9        
  Alcohol consumption (past 12 mo)                  \<0.0001                      
  Abstinent                                         4516 (65)    53.2±21.4        
  Light                                             2117 (30)    58.6±20.5        
  Moderate                                          302 (4)      62.1±19.9        
  Heavy                                             47 (1)       48.8±22.2        
  CHADS~2~ score[\*](#tf1-1){ref-type="table-fn"}   \<0.0001 L                    
  1[\*](#tf1-2){ref-type="table-fn"}                2            33.3±47.1        0.0015 Q
  2                                                 920 (13)     59.3±19.7        
  3                                                 3094 (44)    55.1±21.3        
  4                                                 1963 (28)    54.3±21.7        
  5                                                 852 (12)     53.6±21.3        
  6                                                 152 (2)      53.4±21.5        

Continuous predictors are split at median for summarizing TTR but tested as continuous. Missing data occurred in fewer than 0.2% of records for any variable. Race: for purposes of testing, race groups were white, Asian, and all others. i‐TTR indicates individual patient‐level time in therapeutic range; BMI, body mass index; BP, blood pressure; AF, atrial fibrillation; TIA, transient ischemic attack; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; PAD, peripheral artery disease; GI, gastrointestinal.

CHADS~2~: linear (L) and quadratic (Q) models tested.

CHADS~2~=1: combined with CHADS~2~=2 for testing.

###### 

Mean i‐TTR by Baseline Characteristics: Medication Use

  Baseline Variable                    N           i‐TTR Mean %   Univariable *P* Value
  ------------------------------------ ----------- -------------- -----------------------
  Prior VKA experience                 \<0.0001                   
  VKA naïve                            2596 (37)   47.4±22.1      
  VKA experienced but warfarin naïve   1334 (19)   56.9±19.0      
  Warfarin experienced                 3053 (44)   61.1±19.3      
  Aspirin                              \<0.0001                   
  Absence                              4949 (71)   56.4±20.8      
  Presence                             2034        52.2±22.1      
  ACE inhibitor                        0.070                      
  Absence                              3223        55.7±21.3      
  Presence                             3760 (54)   54.8±21.2      
  ACE inhibitor or ARB                 0.86                       
  Absence                              1808        55.3±21.4      
  Presence                             5175 (74)   55.2±21.2      
  Amiodarone                           \<0.0001                   
  Absence                              6444        55.7±21.2      
  Presence                             539 (8)     49.3±20.6      
  Digitalis                            0.0037                     
  Absence                              4278        55.8±21.3      
  Presence                             2705 (39)   54.3±21.2      
  β‐Blocker                            0.0003                     
  Absence                              2411        53.9±21.8      
  Presence                             4572 (65)   55.8±21.0      
  Loop diuretic                        0.75                       
  Absence                              4577        55.1±21.3      
  Presence                             2406 (34)   55.3±21.3      
  Statin                               \<0.0001                   
  Absence                              3968        52.7±21.6      
  Presence                             3015 (43)   58.4±20.3      

There were no missing data for this Table. i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist; ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker.

Univariable Associations With i‐TTR
-----------------------------------

The overall mean i‐TTR was 55.2% (SD 21.3%), and the median i‐TTR was 57.9% (interquartile range \[IQR\] 43.0% to 70.6%). The mean time with INR \<2 was 29.1%, and the mean time with an INR \>3 was 15.7%. When the definition of therapeutic range was expanded to INR 1.8 to 3.5, the mean time in this therapeutic range was 74.5% (SD 21.8%) and the median was 80.4% (IQR 65.9% to 89.9%). In univariable analysis, multiple patient features were associated with i‐TTR (Tables[1](#tbl01){ref-type="table"} and [2](#tbl02){ref-type="table"}). Younger patients, female patients, those with heart failure, and patients with higher CHADS~2~ scores had lower mean i‐TTR levels. Asian patients had a mean i‐TTR a full 8% lower than did white patients. Patients who reported light to moderate alcohol consumption had higher i‐TTR levels than did those who were alcohol abstinent. Prior experience with warfarin had a notably strong association with i‐TTR. Warfarin‐experienced patients had a mean i‐TTR of 61.1% compared with a mean of 47.4% for VKA‐naïve patients. Patients who had previously taken non--warfarin VKAs had a mean i‐TTR of 56.9%. Multiple other medications taken at entry into the study were statistically associated with i‐TTR. During follow‐up, 2287 patients had ≥1 hospitalizations. There was no decrease in mean i‐TTR among these hospitalized patients compared with those avoiding hospitalization during the trial (data not shown).

Association of Geographic Region and Mean i‐TTR
-----------------------------------------------

There was remarkable variation in mean i‐TTR across geographic regions, ranging from 36% in the small group of patients treated in India to 50% for patients treated in Eastern Europe and East Asia to 63% and 64%, respectively, for patients treated in Western Europe/similar and Canada/United States ([Figure 1](#fig01){ref-type="fig"}a). Across regions, there were marked differences in the proportion of patients naïve to VKAs, ranging from 9.7% of patients in Canada/United States to 53% in Eastern Europe. In Canada/United States, East Asia, and South Africa, the predominant VKA used before the trial was warfarin. But, in the remaining regions, many patients who were VKA experienced were still warfarin naïve (Table[3](#tbl03){ref-type="table"}). Nonetheless, the qualitative regional patterns of i‐TTR across regions persisted after stratification by patients\' experience with VKAs, although the absolute differences in mean TTR were modestly reduced. Patients treated in Canada/United States and Western Europe/similar still had the highest TTRs, whether patients were experienced with warfarin or completely VKA naïve. The point estimates were modestly higher for Western Europe/similar versus Canada/United States in these stratified analyses (Table[3](#tbl03){ref-type="table"}). Country‐level patterns of mean i‐TTR stratified by warfarin experience at baseline are presented in [Figure 1](#fig01){ref-type="fig"}b through [1](#fig01){ref-type="fig"}d.

###### 

Regional Mean i‐TTR by Prior VKA Experience

                                                                        N      i‐TTR, mean %   SE    Median (25th, 75th)   Parameter Estimate   *P* Value
  --------------------------------------------------------------------- ------ --------------- ----- --------------------- -------------------- -----------
  VKA naïve                                                                                                                                     
  East Asia                                                             356    47.3            1.1   49 (34, 63)           −7.75                0.0005
  India                                                                 87     32.6            2.5   29 (13, 49)           −22.46               \<0.0001
  Eastern Europe                                                        1414   45.2            0.6   47 (31, 61)           −9.90                \<0.0001
  Western Europe/similar                                                233    57.8            1.3   62 (48, 72)           2.72                 0.25
  South Africa                                                          29     46.5            4.8   47 (26, 64)           −8.57                0.054
  Latin America                                                         348    50.1            1.1   54 (37, 64)           −5.00                0.025
  Canada/United States                                                  129    55.1            1.8   58 (46, 70)           Ref                  
  VKA experienced but warfarin naïve[\*](#tf3-1){ref-type="table-fn"}                                                                           
  East Asia                                                             0                                                                       
  India                                                                 20     45.5            5.1   47 (28, 63)           −14.72               0.0006
  Eastern Europe                                                        619    53.6            0.8   55 (43, 68)           −6.53                \<0.0001
  Western Europe/similar                                                399    60.1            0.9   63 (50, 73)           Ref                  
  South Africa                                                          0                                                                       
  Latin America                                                         293    60.1            1.0   62 (50, 72)           −0.08                0.96
  Canada/United States                                                  3      64.1            3.8   65 (57, 70)                                
  Warfarin experienced                                                                                                                          
  East Asia                                                             371    53.3            1.1   56 (41, 68)           −11.83               \<0.0001
  India                                                                 23     39.9            4.6   42 (27, 52)           −25.25               \<0.0001
  Eastern Europe                                                        630    55.9            0.7   58 (45, 70)           −9.16                \<0.0001
  Western Europe/similar                                                456    68.7            0.7   70 (60, 79)           3.61                 0.64
  South Africa                                                          95     57.3            2.1   63 (46, 71)           −7.76                \<0.0001
  Latin America                                                         283    56.4            1.2   59 (45, 71)           −8.75                \<0.0001
  Canada/United States                                                  1195   65.1            0.5   67 (55, 78)           Ref                  

i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist.

Because there are only 3 patients in this group in North America, Western Europe is used as the reference instead. There are no patients in this group in East Asia or South Africa.

![A, Overall distribution of mean i‐TTR (%) by country (gray bars), grouped by region (black bars). B, Distribution of mean i‐TTR (%) by country (gray bars), grouped by region (black bars), for patients naïve to vitamin K antagonist therapy at baseline. C, Distribution of mean i‐TTR (%) by country (gray bars), grouped by region (black bars), for patients experienced with vitamin K antagonist therapy but naïve to warfarin treatment at baseline. D, Distribution of mean i‐TTR (%) by country (gray bars), grouped by region (black bars), for warfarin‐experienced patients at baseline. E, Distribution of overall mean i‐TTR (%) by country (gray bars), grouped by region (black bars), excluding the first 90 days in the trial. TTR indicates time in therapeutic range at individual patient level; East Asia: CN, China; HK, Hong Kong; KR, Korea; MY, Malaysia; PH, Philippines; SG, Singapore; TH, Thailand; TW, Taiwan; Eastern Europe: BG, Bulgaria; CZ, Czech Republic; GR, Greece; HU, Hungary; LT, Lithuania; PL, Poland; RO, Romania; RU, Russia; TR, Turkey; UA, Ukraine; Western Europe/similar: AT, Austria; AU, Australia; BE, Belgium; CH, Switzerland; DE, Germany; DK, Denmark; ES, Spain; FI, Finland; FR, France; GB, Great Britain; IL, Israel; IT, Italy; NL, Netherlands; NO, Norway; NZ, New Zealand; SE, Sweden; Latin America: AR, Argentina; BR, Brazil; CL, Chile; CO, Colombia; MX, Mexico; PE, Peru; VE, Venezuela.](jah3-2-e000067-g1){#fig01}

By 90 days, patients newly started on warfarin should have achieved a relatively stable dose. Analyses excluding the first 90 days of follow‐up resulted in improved regional mean i‐TTRs, particularly in regions with a high proportion of patients naïve to warfarin. Despite these changes, the regional‐ (Table[4](#tbl04){ref-type="table"}) and country‐level (Figure[1](#fig01){ref-type="fig"}e) differences persisted. When we further stratified these analyses starting at 90 days by patients\' previous exposure to warfarin and VKAs, the regional TTR patterns were preserved (data not shown).

###### 

Regional Mean i‐TTR After First 90 Days of Follow‐up

  Region                   N      i‐TTR, mean %   SD     Median (25th, 75th)   Parameter Estimate   *P* Value
  ------------------------ ------ --------------- ------ --------------------- -------------------- -----------
  East Asia                677    53.3            21.7   56 (40, 67)           −12.52               \<0.0001
  India                    115    39.5            25.2   42 (21, 56)           −26.38               \<0.0001
  Eastern Europe           2462   53.0            21.5   55 (40, 68)           −12.82               \<0.0001
  Western Europe/similar   1019   66.6            17.7   69 (58, 79)           0.76                 0.37
  South Africa             115    57.6            21.1   59 (46, 74)           −8.19                \<0.0001
  Latin America            875    59.0            20.0   61 (48, 74)           −6.84                \<0.0001
  Canada/United States     1244   65.8            18.7   68 (56, 79)           Ref                  

i‐TTR indicates individual patient‐level time in therapeutic range.

Multivariable Associations With i‐TTR
-------------------------------------

In multiple linear regression models of mean i‐TTR, many features remained statistically significant (Table[5](#tbl05){ref-type="table"}). Particularly strong effects were seen for patients who were VKA naïve (−9.1%, compared with warfarin experienced), women (−9.3%), patients with heart failure (−3.2%), patients with chronic obstructive pulmonary disease (−2.9%), patient using amiodarone at study entry (−3.6%), and across categories of use of alcohol. Even after adjustment for all other significant features (but leaving out race because of collinearity with region), the effect of geographic region remained remarkable. With Canada/United States patients as the referent group, the mean i‐TTR was an absolute 8.6% lower for patients in Eastern Europe, 8.7% lower in East Asia, 4.7% lower in Latin America, and essentially the same for patients treated in Western Europe/similar. The small sample of patients in India had a particularly low average i‐TTR. Although there were several strong determinants of mean i‐TTR, the overall multivariable model *R*^2^ was only 16%. By percent of variance explained (ie, partial *R*^2^), the strongest risk factors were VKA experience (3.7%) and geographic region (4.3%).

###### 

Predictors of i‐TTR (%) in Warfarin Patients by Multiple Linear Regression Modeling[\*](#tf5-1){ref-type="table-fn"}: Geographical Site of Recruitment Grouped as Regions

  Baseline Characteristic             Multivariable                       
  ----------------------------------- --------------- -------- ---------- --------
  VKA experience                                                          
  Warfarin experienced                Ref             129.71   \<0.0001   0.0374
  VKA experienced/warfarin naïve      −2.221                              
  VKA naïve                           −9.138                              
  Region                                                                  
  Canada/United States                Ref             49.24    \<0.0001   0.0426
  Western Europe/similar              0.680                               
  Latin America                       −4.692                              
  South Africa                        −8.347                              
  Eastern Europe                      −8.598                              
  East Asia                           −8.680                              
  India                               −20.559                             
  CHF                                 −3.172          37.05    \<0.0001   0.0053
  Female                              −9.324          22.74    \<0.0001   0.0033
  COPD                                −2.859          13.34    0.0003     0.0019
  eGFR, 10 mL/min per 1.73 m^2^       0.0030                              
  Linear                              −6.474          11.36    0.0008     
  Quadratic                           0.169           4.77     0.029      
  Hemoglobin, 2 g/L                   0.0029                              
  Linear                              −8.794          11.17    0.0008     
  Quadratic                           0.276           5.02     0.025      
  Systolic BP                         −0.0453         9.39     0.0022     0.0014
  BMI                                 0.0022                              
  Linear                              0.677           7.38     0.0066     
  Quadratic                           −0.0086         5.13     0.024      
  Diabetes                            −1.208          5.77     0.016      0.0008
  Alcohol consumption, 12 mo                                              
  Abstinent                           Ref             5.76     0.0006     0.0025
  Light                               1.772                               
  Moderate                            3.012                               
  Heavy                               −4.921                              
  Medications at entry to the trial                                       
  Amiodarone                          −3.608          16.42    \<0.0001   0.0024
  Statin                              1.682           11.36    0.0008     0.0016
  Aspirin                             −1.111          4.10     0.043      0.0006

i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; BP, blood pressure; BMI, body mass index.

For the multivariable model results reported in [Table 4](#tbl04){ref-type="table"}a through [4](#tbl04){ref-type="table"}c, n=6961 with 22 subjects omitted because of missing covariate values.

Variation in i‐TTR Across Countries
-----------------------------------

There was substantial variation in i‐TTR across the 45 countries in ROCKET AF, ranging from a mean of 36% to 75%. Substitution of individual countries for geographic regions in the multiple linear regression model led to an increase in the overall model *R*^2^ from 16% to 19% (Table[6](#tbl06){ref-type="table"}). Even within regions, there was considerable variability across countries (Figure[1](#fig01){ref-type="fig"}). Of particular interest, the mean TTR was 47% in China and 38% in Taiwan but 66% in Hong Kong and 64% in Singapore. Ninety‐nine percent of the patients in all 4 of these regions were identified as being of Asian race. When we substituted patient\'s race for patient\'s region in the multivariable model, the overall model *R*^2^ deteriorated to 12.8% (Table[7](#tbl07){ref-type="table"}).

###### 

Predictors of i‐TTR (%) in Warfarin Patients by Multiple Linear Regression Modeling: Geographical Site of Recruitment Grouped as Countries

  Baseline Characteristic             Multivariable                         
  ----------------------------------- --------------- ---------- ---------- --------
  VKA experience                      74.94           \<0.0001   0.0217     
  Warfarin experienced                Ref                                   
  VKA experienced/warfarin naïve      −7.399                                
  VKA naïve                           −2.153                                
  CHF                                 −2.373          20.19      \<0.0001   0.0029
  Country                             13.73           \<0.0001   0.0876     
  United States                       Ref                                   
  Argentina                           −1.486                                
  Australia                           7.531                                 
  Austria                             5.945                                 
  Belgium                             −3.014                                
  Brazil                              −7.721                                
  Bulgaria                            −9.669                                
  Canada                              2.801                                 
  Chile                               −0.302                                
  China                               −11.081                               
  Colombia                            −8.315                                
  Czech Republic                      −1.641                                
  Denmark                             1.548                                 
  Finland                             4.294                                 
  France                              1.180                                 
  Germany                             −1.600                                
  Greece                              −7.210                                
  Hong Kong                           3.003                                 
  Hungary                             −3.170                                
  India                               −21.495                               
  Israel                              −4.492                                
  Italy                               3.818                                 
  Korea                               −14.885                               
  Lithuania                           −10.173                               
  Malaysia                            −4.867                                
  Mexico                              −10.713                               
  Netherlands                         −0.160                                
  New Zealand                         9.905                                 
  Norway                              4.564                                 
  Peru                                −2.116                                
  Philippines                         −3.744                                
  Poland                              −1.884                                
  Romania                             −10.103                               
  Russia                              −10.903                               
  Singapore                           2.828                                 
  South Africa                        −7.806                                
  Spain                               −2.821                                
  Sweden                              12.009                                
  Switzerland                         −10.068                               
  Taiwan                              −20.772                               
  Thailand                            −3.865                                
  Turkey                              −16.503                               
  Ukraine                             −13.930                               
  United Kingdom                      6.014                                 
  Venezuela                           −20.635                               
  COPD                                −2.669          11.91      0.0006     0.0017
  Female                              −6.275          10.24      0.0014     0.0015
  Diabetes                            −1.598          10.22      0.0014     0.0015
  BMI                                 0.0022                                
  Linear                              0.744           9.14       0.0025     
  Quadratic                           −0.010          6.58       0.010      
  Systolic BP                         −0.037          6.28       0.012      0.0009
  Hemoglobin, 2 g/L                   0.0014                                
  Linear                              −4.654          3.11       0.078      
  Quadratic                           0.109           0.78       0.38       
  eGFR, 10 mL/min per 1.73 m^2^       0.0013                                
  Linear                              −3.478          3.26       0.071      
  Quadratic                           0.073           0.90       0.34       
  Alcohol consumption, 12 mo          2.41            0.065      0.0010     
  Abstinent                           Ref                                   
  Light                               0.838                                 
  Moderate                            1.624                                 
  Heavy                               −5.340                                
  Medications at entry to the trial                                         
  Amiodarone                          −2.616          8.74       0.0031     0.0013
  Statin                              0.818           2.63       0.11       0.0004
  Aspirin                             −0.619          1.25       0.26       0.0002

i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate.

###### 

Predictors of i‐TTR (%) in Warfarin Patients by Multiple Linear Regression Modeling Using Race in Model Rather Than Region

  Baseline Characteristic             Multivariable                         
  ----------------------------------- --------------- ---------- ---------- --------
  VKA experience                      239.37          \<0.0001   0.0690     
  Warfarin experienced                Ref                                   
  VKA experienced/warfarin naïve      −11.965                               
  VKA naïve                           −4.149                                
  CHF                                 −4.942          92.90      \<0.0001   0.0132
  Female                              −14.294         37.94      \<0.0001   0.0054
  Race                                20.47           \<0.0001   0.0088     
  White                               Ref                                   
  Black                               1.924                                 
  Asian                               −5.919                                
  Other                               −3.836                                
  eGFR, 10 mL/min per 1.73 m^2^       0.0048                                
  Linear                              −11.123         24.26      \<0.0001   
  Quadratic                           0.331           14.26      0.0002     
  Hemoglobin, 2 g/L                   0.0043                                
  Linear                              −15.327         24.42      \<0.0001   
  Quadratic                           0.559           15.92      \<0.0001   
  Systolic BP                         −0.055          13.42      0.0003     0.0019
  Alcohol consumption, 12 mo          10.09           \<0.0001   0.0044     
  Abstinent                           Ref                                   
  Light                               2.427                                 
  Moderate                            4.541                                 
  Heavy                               −3.944                                
  COPD                                −2.305          8.44       0.0037     0.0012
  BMI                                 0.0022                                
  Linear                              0.422           2.80       0.095      
  Quadratic                           −0.004          1.13       0.29       
  Diabetes                            −0.638          1.57       0.21       0.0002
  Medications at entry to the trial                                         
  Amiodarone                          −4.395          23.89      \<0.0001   0.0034
  Statin                              2.568           26.35      \<0.0001   0.0038
  Aspirin                             −0.782          2.02       0.16       0.0003

i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; BP, blood pressure; COPD, chronic obstructive pulmonary disease; BMI, body mass index.

Distribution of INR Values and Management of Test Results
---------------------------------------------------------

Geographic regional variation in mean i‐TTR levels was largely due to time at INR \<2.0 (Figure[2](#fig02){ref-type="fig"}, Table[8](#tbl08){ref-type="table"}). For Canada/United States patients, the mean time at INR \<2.0 was 19.9%. In contrast, for Eastern European patients, the mean time at INR \<2.0 was 35.2%, and for patients in East Asia, the time at INR \<2.0 was 37.1%. The differences in mean time at INR \>3.0 were much smaller and contributed much less to the differences in i‐TTR across regions. If we define "dangerously" low as INR \<1.7, the regional pattern persisted with patients in Canada/United States and Western Europe/similar dangerously low ≈8% of the time compared with 19.7% of the time in Eastern Europe and 18.8% in East Asia. Canada/US and Western Europe/similar centers were in the "expanded" therapeutic range of INR 1.8 to 3.5 a mean of 84% and 83% of the time, respectively. By contrast, patients in East Asia and Eastern Europe were in this expanded range ≈70% of the time.

###### 

i‐TTR, Time in Other INR Ranges, and INR Test Results and Frequency by Region

  Parameter                                         Region                                                                                                                  
  ------------------------------------------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- ---------
  i‐TTR                                                                                                                                                                     
  i‐TTR (INR 2.0 to 3.0, %)                         N (patients)   6983           727            130            2663           1088           124            924            1327
  Mean±SD                                           55.2±21.27     50.4±21.42     35.9±23.34     49.7±21.16     63.2±18.48     54.8±22.011    55.2±20.00     64.1±18.23     
  (25th, 75th percentile)                           (43.0, 70.6)   (37.6, 64.8)   (18.6, 50.7)   (36.8, 64.8)   (53.7, 75.9)   (42.9, 70.6)   (44.5, 69.3)   (54.8, 77.0)   
  Time above TR (INR \>3.0, %)                      N              6983           727            130            2663           1088           124            924            1327
  Mean±SD                                           15.7±13.13     12.6±12.83     20.0±21.34     15.1±12.61     16.5±13.20     21.3±18.10     17.4±12.95     16.0±12.28     
  (25th, 75th percentile)                           (7.0, 21.5)    (3.7, 17.0)    (6.1, 25.5)    (6.2, 21.2)    (7.4, 22.7)    (8.7, 28.3)    (9.0, 23.5)    (8.3, 21.1)    
  Time below TR (INR \<2.0, %)                      N              6983           727            130            2663           1088           124            924            1327
  Mean±SD                                           29.1±21.94     37.1±23.00     44.1±25.87     35.2±22.78     20.2±17.88     23.9±23.25     27.4±20.01     19.9±16.16     
  (25th, 75th percentile)                           (13.6, 38.6)   (20.6, 51.0)   (25.2, 61.0)   (19.2, 46.3)   (8.7, 26.2)    (7.3, 32.9)    (14.2, 34.1)   (9.1, 26.7)    
  Time dangerously out of range---low (INR \<1.7)   N              6983           727            130            2663           1088           124            924            1327
  Mean±SD                                           14.8±19.10     18.8±19.92     30.9±25.73     19.7±21.58     8.0±13.19      11.9±18.61     13.8±17.77     7.7±11.74      
  (25th, 75th percentile)                           (2.7, 18.7)    (5.6, 27.0)    (13.6, 48.0)   (5.2, 26.1)    (1.1, 9.5)     (1.1, 14.2)    (3.2, 15.9)    (1.2, 9.7)     
  Time in INR range of 1.8 to 3.5                   N              6983           727            130            2663           1088           124            924            1327
  Mean±SD                                           74.5±21.75     69.9±22.37     51.8±27.30     68.8±22.90     82.7±17.19     75.6±23.62     74.8±20.36     83.6±15.64     
  (25th, 75th percentile)                           (65.9, 89.9)   (59.2, 85.9)   (33.1, 72.2)   (58.6, 85.7)   (77.1, 94.1)   (69.9, 90.8)   (67.8, 88.4)   (78.2, 93.8)   
  INR tests (multiple observations/patient)         N (tests)      181 640        17 218         2415           64 644         30 439         3131           22 134         41 659
  Average INR                                                                                                                                                               
  Mean±SD                                           2.4±0.87       2.3±0.83       2.4±1.21       2.4±0.93       2.5±0.80       2.5±0.86       2.4±0.92       2.5±0.78       
  Median                                            2.3            2.2            2.1            2.2            2.4            2.4            2.3            2.4            
  (25th, 75th percentile)                           (1.8, 2.8)     (1.7, 2.7)     (1.5, 2.8)     (1.7, 2.8)     (2.0, 2.9)     (1.9, 2.9)     (1.8, 2.8)     (2.0, 2.9)     
  Average No. of tests/patient                      Mean±SD        26±13.3        24±10.8        19±11.5        24±11.6        28±13.9        25±10.9        24±10.6        31±17.0
  (25th, 75th percentile)                           (18, 34)       (17, 32)       (8, 27)        (17, 32)       (19, 37)       (19, 33)       (17, 31)       (19, 43)       
  Average No. of days between INR measurements      N              6983           727            130            2663           1088           124            924            1327
  Mean±SD                                           21±5.1         23±4.7         22±5.6         23±5.0         20±5.3         21±4.8         22±4.3         19±4.8         
  (25th, 75th percentile)                           (19, 25)       (22, 26)       (20, 26)       (21, 26)       (16, 24)       (19, 24)       (20, 25)       (17, 23)       

i‐TTR indicates individual patient‐level time in therapeutic range; INR, international normalized ratio.

![Distribution of times in therapeutic (INR 2.0 to 3.0), low, and high INR range by geographic region. INR indicates international normalized ratio.](jah3-2-e000067-g2){#fig02}

The distributions of INR values confirmed that lower i‐TTRs resulted primarily from subtherapeutic INR levels (Table[8](#tbl08){ref-type="table"}). The median INR was 2.4 for patients in Canada/United States and Western Europe/similar but 2.2 for patients in Eastern Europe and East Asia and 2.3 for patients in Latin America. The distributions were narrower in Canada/United States and Western Europe/similar with IQRs of 0.9 INR unit compared with East Asia and Latin America with IQRs of 1.0 INR unit and Eastern Europe with an IQR of 1.1 INR units (all *P\<*0.001)

We compared the average number of days between INR measurements (Figure[3](#fig03){ref-type="fig"}, Table[8](#tbl08){ref-type="table"}). Patients in Canada/United States and Western Europe had the most frequent INR tests at an average interval of 19 and 20 days, respectively. By contrast, patients in Eastern Europe and in East Asia had the least frequent INR testing with an average interval of 23 days (*P\<*0.001). We extended this analysis to compare the time to subsequent INR after an extreme INR value. There was marked variation in median time to a follow‐up INR test after an INR ≤1.5, from 9 days in Western Europe/similar and Canada/United States to 26 and 27 days in Eastern Europe and East Asia, respectively (*P\<*0.001). Similarly, the median time to a subsequent INR test after an INR ≥4.0 was 7 days in Western Europe/similar and Canada/United States versus 25 and 23 days in Eastern Europe and East Asia, respectively (*P\<*0.001). Figure[3](#fig03){ref-type="fig"} displays the distribution of mean inter‐test intervals as a function of initial INR test result. There is an inverted "U" pattern seen in all regions but inter‐test intervals were shortest in regions with the highest TTRs, regardless of initial test result.

![Inter‐INR test interval by value of first INR, stratified by geographic region. INR indicates international normalized ratio; TTR, time in therapeutic range.](jah3-2-e000067-g3){#fig03}

Discussion
==========

The linearly interpolated TTR has become a widely accepted measure of the quality of anticoagulation management.^[@b7]^ In the ROCKET AF trial, the mean i‐TTR for patients assigned to warfarin was 55%, lower than that reported for other recent trials of novel anticoagulants,^[@b17]--[@b19]^ with a wide range of i‐TTR values. The ROCKET AF trial enrolled patients at particularly high risk of stroke. One of these stroke risk factors, heart failure, was associated with an adjusted 3% decrease in average i‐TTR. However, other standard stroke risk factors in AF (ie, prior stroke/TIA, hypertension, and diabetes) had only modest, if any, univariate effects on i‐TTR and none was selected as a significant predictor of i‐TTR in our multivariable model. The 2 strongest determinants of i‐TTR (by partial *R*^2^) were not patient comorbidities but rather pretrial experience with warfarin and geographic site. Patients who were taking warfarin before entry into the trial had an adjusted absolute 9% higher mean i‐TTR than those who were VKA naïve. Interregional mean i‐TTR varied by as much as 21%, even after accounting for patient clinical features and experience with warfarin. Excluding the small number of patients treated in India, interregional differences in mean i‐TTR still spanned an absolute 8.7%. Excluding the first 90 days of warfarin treatment, to allow warfarin‐naïve patients to become warfarin‐experienced, still resulted in large interregional differences in mean TTR. When country was included in the model instead of region, the total variance explained increased. Large regional effects on TTR with similar geographic patterns have been observed in other recent trials.^[@b8],[@b20]^

Poorer i‐TTR primarily reflected INR values below 2.0. The risk of stroke among patients with AF rises steeply the lower the INR value below 2.0.^[@b1]^ The TTR does not distinguish low from very low INR values. When we assessed time in dangerously low INR range (ie, INR \<1.7) the regional differences persisted. When we focused specifically on the regional distributions of INR values, we found the lower the mean i‐TTR, the lower the mean INR. For East Asia, in particular, the IQR of INR values was nearly as narrow as that for the regions with higher TTRs, suggesting that physicians were implicitly targeting the low end of the target range of INR 2.0 to 3.0. The fact that the mean TTR for patients treated in Hong Kong and Singapore was much higher than the mean TTR in the remaining countries in East Asia indicates that medical care practices and not race determine anticoagulation control in this region.^[@b21]^ We found, as well, that regions with lower TTR values obtained INR tests less frequently. While follow‐up test intervals were shorter the more extreme the initial INR results, the intervals were still longer in regions with the lowest TTR. Rose et al have proposed as a quality indicator the time to follow‐up INR after an INR ≤1.5 or ≥4.0.^[@b22]^ We found longer test intervals after such extreme INR values in regions with lower mean TTRs.

We have used the distinctively large and geographically diverse cohort of warfarin‐treated patients in the ROCKET AF trial to add to our understanding of the determinants of TTR. Our study benefits from the high quality of information captured at study entry, close longitudinal follow‐up, and standardized INR testing with a single type of point‐of‐care device. There was comprehensive recording of clinically scheduled INR test results. As a consequence of the trial protocol, patients did not go for long periods (ie, \>8 weeks) without an INR test, consistent with guideline recommendations.^[@b14]^ This is in contrast to usual clinical care where the distribution of test intervals is broader, adding uncertainty to the calculation of TTR.^[@b23]^

Our study has limitations. As always, our trial‐based results may not generalize completely to usual clinical care. Our regional findings reflect the care provided by a limited set of investigators in any geographic region. As such, we cannot claim that our findings are clearly representative of warfarin management in participating countries. However, it is notable that the regional pattern of our results is similar to those reported by the ACTIVE W trial for the countries where both trials recruited patients.^[@b8]^ In particular, in both the ROCKET AF and ACTIVE W trials the country with the highest i‐TTR was Sweden and a recent survey of anticoagulation in clinical care in Sweden reported a mean i‐TTR of 74%, nearly identical to the value of 75% observed in the ROCKET AF trial.^[@b24]^ We cannot account for the resource constraints or cultural norms underlying different regional practices in managing warfarin. The widely used Rosendaal measurement of i‐TTR uses linear interpolation to impute daily INR values. Other imputation approaches might reduce interregional differences in i‐TTR. Ultimately, while i‐TTR makes sense as a measure of the quality of warfarin management, its quantitative relationship to the net benefit of warfarin therapy is still uncertain.

In conclusion, we found that patient clinical features, such as heart failure, were significant but modest determinants of i‐TTR. Further, we were able to quantify the reduced control of warfarin anticoagulation faced by new users of the drug. However, our most notable finding was the striking influence of geographic region, presumably reflecting different levels of aggressiveness in achieving the INR point target of 2.5, different support systems to manage warfarin, and different regional barriers to frequent INR testing and warfarin dose changes. Such geographic variation in medical practice has become a truism of health care epidemiology.^[@b25]--[@b26]^ While our understanding of the determinants of i‐TTR remains incomplete, it is clear that the providers of care, and the systems within which they work, have a profound effect on the quality of anticoagulation.
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